Articles On Dimerix (ASX:DXB)

Dimerix (ASX:DXB) has announced that the independent Data Safety Monitoring Board has successfully concluded a second review of the ACTION3 phase 3 clinical trial.

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix (ASX:DXB) has confirmed that the first 72 patients have been randomised in its DMX-200 ACTION3 phase 3 trial in patients with FSGS kidney disease.

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix has achieved a key milestone in its global Phase 3 Focal Segmental Glomerulosclerosis (FSGS) trial with the last patient of the first 72 patient cohort  now randomised, locking in a March 2024 date for interim outcome results.   Dim...

Futures suggest the ASX will open higher before the release of Australia’s inflation figures and the interest rate decisions from the Federal Reserve and ECB. Meanwhile, the Aussie dollar is down 0.7 per cent to 67.29 US cents. Here...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Peak Asset Management recently held its first Microcaps investor conference, and here’s what the punters and players had to say about it. In mid July, boutique firm Peak Asset Management organised its inaugural microcap investor conference,...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix (ASX:DXB) has announced that the Paediatric Committee of the European Medicines Agency has accepted its Paediatric Investigation Plan for the development of DMX-200 for focal segmental glomerulosclerosis following the PDCO m...

Peak Asset Management, with the support of Stockhead, is giving you the chance to go 1-on-1 with some of the leading ASX small caps CEOs and property gurus from a range of market sectors in Melbourne, on 13 July, 2023. The hectic landscape...

In a major milestone, Dimerix has received endorsement by the European Medicines Agency (EMA) to include children in Europe in its pivotal ACTION3 trial. Dimerix (ASX:DXB) has announced  that the Paediatric Committee (PDCO) of the EMA has...

Futures suggest the ASX will climb as the new financial year takes off, bolstered by hopes that the RBA will hit pause ahead of its next rates decision tomorrow. Here are some ASX-listed companies with news out today: Larvotto Resourc...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

In a tough market environment Dimerix has announced it has raised close to $9 million as it moves to advance its Phase 3 Focal Segmental Glomerulosclerosis (FSGS) clinical trial past first interim data. Clinical stage biopharmaceutical comp...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead’s In-Case-You-Missed-It highlights some of the strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some of the strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Stockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage...

Stockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Dimerix is looking to raise $12 million to continue its phase 3 Focal Segmental Glomerulosclerosis (FSGS) clinical trial past first interim data. Clinical stage biopharmaceutical company Dimerix (ASX:DXB) has announced a $12 million capita...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Renewable energy technology business Synertec and drug developer Dimerix are expected to return to trading on Wednesday morning, after stitching up equity raisings.

The benchmark kicked off well at +0.8% before deflating to finish on +0.4% Utilities (+1.21%)win the day, while InfoTech (-1.20%) takes a body blow. Lincoln Minerals (ASX:LML) tops the charts, up 36% for absolutely no reason at all.   Loc...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.  In this episode Tim chats to Nina Webster, CEO & managing direct...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped below the radar today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage t...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

Dimerix has welcomed news late last week that the US Food and Drug Administration (FDA) has approved the drug Sparsentan for Immunoglobulin A nephropathy (IgAN) another type of rare (orphan) kidney disease. The company says this approval is...

Dimerix (DXB) is set to pocket $2.8 million as a prepayment of a research and development (R&D) tax incentive claim DX8 penned a funding deal with Radium Capital to gain early access to the equivalent of 80 per cent of its accrued R&...

Dimerix has announced another milestone for its pivotal Phase-3 trial with a positive report on a key review evaluating available study data for participant safety, study conduct and progress. ASX listed biotech Dimerix (ASX:DXB) today con...